Chronic alveolar hypoventilation for md exam answer 10 marks from fishman and Murray only
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have sufficient information from both Fishman's and Murray & Nadel to write a comprehensive 10-mark exam answer. Let me compile this.
Chronic Alveolar Hypoventilation
10-Mark MD Exam Answer | Sources: Fishman's Pulmonary Diseases and Disorders; Murray & Nadel's Textbook of Respiratory Medicine
Definition
Chronic alveolar hypoventilation (CAH) refers to a sustained reduction in alveolar ventilation relative to metabolic CO2 production, resulting in a chronically elevated arterial PaCO2 (hypercapnia). Because the lungs themselves are normal in the primary form, CAH is physiologically distinct from CO2 retention caused by ventilation-perfusion (V/Q) mismatch in intrinsic lung disease.
As stated in Murray & Nadel's: alveolar ventilation is the volume of fresh inspired gas reaching the alveoli (non-dead-space ventilation); any sustained reduction forces the alveolar PCO2 to settle at a higher level, governed by:
PaCO2 = VCO2 / VA × K
where VA is alveolar ventilation. If VA is halved, PaCO2 doubles (at steady state). Reciprocally, alveolar PO2 falls by nearly the same amount, producing hypoxemia even in the presence of structurally normal lungs.
- Murray & Nadel's Textbook of Respiratory Medicine, block 3
Classification and Causes
Both texts classify CAH according to whether the primary problem is "won't breathe" (defective ventilatory drive) or "can't breathe" (intact drive but mechanical or neuromuscular failure). Fishman's uses the ICSD-3 framework:
1. Disorders of Ventilatory Control ("Won't Breathe")
| Category | Examples |
|---|---|
| Central - Congenital | Congenital central alveolar hypoventilation syndrome (CCHS / Ondine's curse) - PHOX2B gene mutation |
| Central - Acquired | Brainstem tumors, Chiari malformation, cerebrovascular disease, encephalitis, high cervical cord lesions |
| Drug/Toxin-induced | Opiates, sedatives, anesthetics |
| Idiopathic | Primary idiopathic alveolar hypoventilation (no structural cause found) |
2. Disorders of Neuromuscular/Chest Wall Mechanics ("Can't Breathe")
- Anterior horn cell diseases (poliomyelitis, ALS)
- Peripheral neuropathy (Guillain-Barre)
- Neuromuscular junction disease (myasthenia gravis)
- Myopathies (progressive muscular dystrophy, acid maltase deficiency)
- Chest wall deformities (kyphoscoliosis)
- Upper airway obstruction
3. Obesity Hypoventilation Syndrome (OHS)
Defined by obesity (BMI ≥30 kg/m²) + chronic awake hypercapnia (PaCO2 ≥45 mmHg) in absence of other causes. Fishman's notes that OHS patients have impaired chemosensitivity to both hypercapnia and hypoxemia, and a subset develop polycythemia, pulmonary hypertension, and cor pulmonale.
- Fishman's Pulmonary Diseases and Disorders, block 21
Pathophysiology
The central mechanism is insufficient alveolar ventilation to excrete metabolically produced CO2. The key equation from Fishman's:
PaCO2 = CO2 production / (MV - MVs)
where MV is total minute ventilation and MVs is dead-space minute ventilation. Hypercapnia results from: (1) decreased minute ventilation, (2) increased dead-space ventilation, or rarely (3) increased CO2 production.
Sleep worsens hypoventilation significantly. In normal sleep, PaCO2 rises by no more than 6 mmHg. In patients with any of the above disorders, sleep abolishes the "wakefulness drive to breathe" (behavioral/cortical drive), leaving ventilation entirely dependent on the already defective metabolic-chemical control system. As Murray & Nadel explains: "the full impact of such defects becomes most apparent during sleep, when non-chemical waking neural drive to breathing is abolished... so that breathing becomes critically dependent on the defective metabolic respiratory control system." Nocturnal hypoventilation therefore typically precedes and drives the development of chronic diurnal hypercapnia.
- Murray & Nadel's Textbook of Respiratory Medicine, block 28; Fishman's block 21
Compensation: Renal retention of HCO3- normalizes pH. This is why an elevated serum bicarbonate (≥27 mEq/L) on blood tests suggests chronic, not acute, hypercapnia.
Clinical Features
Symptoms are often insidious and overlap with the underlying disease:
- Morning headaches (CO2 retention overnight causing cerebral vasodilation)
- Hypersomnolence and fatigue (nocturnal sleep fragmentation, daytime CO2 narcosis)
- Dyspnea on exertion, later at rest
- Cognitive impairment, personality change in advanced cases
- Cyanosis with or without clubbing
Physical signs of chronic complications:
- Plethora, injected sclerae (polycythemia)
- Prominent P2, right ventricular heave (pulmonary hypertension)
- Peripheral edema, raised JVP (cor pulmonale, right heart failure)
In OHS specifically, Murray & Nadel notes: "physical examination may reveal facial plethora, injected sclera, a prominent pulmonic component of the second heart sound, and signs of right heart failure."
Diagnosis
Arterial Blood Gas (ABG)
The cornerstone. Elevated PaCO2 (>45 mmHg) with compensated respiratory acidosis (elevated HCO3-, near-normal pH) = chronic alveolar hypoventilation. An acute-on-chronic picture shows further pH drop with a disproportionate PaCO2 rise.
Serum Bicarbonate
A serum HCO3- ≥27 mEq/L is sensitive (92%) but not specific (50%) for chronic hypercapnia (Fishman's). Confounded by CKD and loop diuretics.
Alveolar-Arterial PO2 Gradient (A-a gradient)
In pure hypoventilation with normal lungs, the A-a gradient is normal - hypoxemia is entirely accounted for by the rise in PaCO2 via the alveolar gas equation. An elevated A-a gradient implies coexistent V/Q mismatch or parenchymal disease.
Pulmonary Function Testing
Normal in pure hypoventilation syndromes (distinguishes from COPD/ILD). Neuromuscular disease gives a restrictive pattern with reduced maximal inspiratory/expiratory pressures (MIP/MEP).
Polysomnography (PSG)
Essential to characterize sleep-related hypoventilation. An increase in PaCO2 of >10 mmHg during sleep, or PaCO2 >55 mmHg for ≥10 minutes, meets the AASM criteria for sleep-related hypoventilation. End-tidal CO2 (ETCO2) or transcutaneous PaCO2 monitoring during PSG is recommended in all at-risk patients.
Additional Workup
Chest imaging, ECG, PHOX2B gene testing (if CCHS suspected), thyroid function, and evaluation for neuromuscular disease as guided by history.
- Fishman's, block 21; Murray & Nadel's, block 27-28
Treatment
Principles
- Treat the underlying cause where possible (e.g., thyroid replacement in hypothyroidism, tumor resection, opiate dose reduction)
- Augment ventilation - the mainstay
- Avoid respiratory depressants (sedatives, opiates)
Noninvasive Ventilation (NIV)
The cornerstone of management for most CAH syndromes. The AASM 2010 best clinical practice guideline for NIV in chronic alveolar hypoventilation recommends titration polysomnography (if feasible) to optimize settings and minimize patient-ventilator asynchrony.
- Bilevel PAP (BPAP/BiPAP): Delivers separate inspiratory (IPAP) and expiratory (EPAP) pressures; most commonly used.
- Volume-assured pressure support (VAPS): Automatically adjusts pressure to maintain a target tidal volume; useful when ventilatory needs fluctuate.
- Target: PaCO2 <45 mmHg awake, <50 mmHg asleep; SaO2 ≥90%.
- Many patients require only nocturnal NIV, which can normalize daytime blood gases.
Murray & Nadel states: "The aim of noninvasive ventilation is to reduce PaCO2 below 45 mm Hg while awake and below 50 mm Hg while asleep and maintaining SaO2 at or above 90%."
CPAP
Effective when OSA is the predominant mechanism (e.g., OHS with predominantly obstructive events).
Supplemental Oxygen
Can relieve hypoxia and CSA, but must be used with caution - may abolish hypoxic ventilatory drive and worsen CO2 retention. Must be accompanied by PaCO2 monitoring.
Pharmacologic
- Medroxyprogesterone (respiratory stimulant): Useful in some cases of idiopathic or OHS-related hypoventilation; successful in a minority.
- Acetazolamide: Can reduce CSA by inducing mild metabolic acidosis to stimulate ventilation, but limited role in CAH.
Tracheostomy and Invasive Mechanical Ventilation
Reserved for progressive disease unresponsive to NIV, bulbar involvement limiting NIV tolerance, or acute respiratory failure.
Weight Loss (OHS)
Substantial weight loss improves or resolves OHS - behavioral, pharmacologic, or bariatric surgical approaches should be pursued alongside ventilatory support.
- Fishman's, blocks 21 and 30; Murray & Nadel's, block 28
Summary Table
| Feature | Characteristic in CAH |
|---|---|
| PaCO2 | Chronically elevated >45 mmHg |
| pH | Normal-near normal (renal compensation) |
| HCO3- | Elevated (>27 mEq/L) |
| A-a gradient | Normal (in pure hypoventilation) |
| Lungs | Structurally normal in primary CAH |
| Key mechanism | ↓ alveolar ventilation → ↑ PaCO2, ↓ PaO2 |
| Sleep | Worsens due to loss of wakefulness drive |
| Complications | Polycythemia, pulmonary HTN, cor pulmonale |
| Treatment | NIV (nocturnal), treat cause, avoid sedatives |
Key Citations:
- Fishman's Pulmonary Diseases and Disorders, 2-Volume Set (ISBN 9781260473940): Chapters on Sleep-Related Hypoventilation (block 21) and NIV management (block 30)
- Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume (ISBN 9780323655873): Chapters on Gas Exchange/Hypoventilation physiology (block 3), Sleep-Related Breathing Disorders and Central Alveolar Hypoventilation Syndrome (block 28)
This is a shared conversation. Sign in to Orris to start your own chat.